Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial

References

• Coryell W Scheftner W Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993;150:720–7
   Google Scholar
• Woods SW The economic burden of bipolar disease. J Clin Psychiatry 2000;61:38–41
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-depressive illness. New York (NY): Oxford University Press; 1990
   Google Scholar
• Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. J Am Med Assoc 2003;290: 1467–73
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. J Am Med Assoc 2003;290:1517–9
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000;61:19–25
   PubMed Web of Science ®Google Scholar
• Baldessarini R, Tondo L, Hennen J. Treatment delays in bipolar disorders. Am J Psychiatry 1999;156:811–2
   PubMed Web of Science ®Google Scholar
• Keck P McElroy S, Strackowski S. 12-month outcomes of patients with bipolar disorder following hospitalization for a major or mixed episode. Am J Psychiatry 1998;155:646–52
   PubMed Web of Science ®Google Scholar
• Bowden CL. Diagnosis of bipolar disorders: focus on bipolar disorder I and bipolar disorder II. Medscape Psychiatry Ment Health J 2002;7
   Google Scholar
• Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 2001;3:165–73
   Google Scholar
• Li J, McCombs J, Stimmel G. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord 2002;71:131–9
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness – 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30: 213–9
   PubMed Web of Science ®Google Scholar
• Tohen M, Waternaux CM, Tsuang MT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47: 1106–11
   Google Scholar
• Mueser KT, Webb C, Pfeiffer M, Gladis M, Levinson DF. Family burden of schizophrenia and bipolar disorder: perceptions of relatives and professionals. Psychiatr Serv 1996;47:507–11
   Google Scholar
• Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US – an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483–95
   PubMed Web of Science ®Google Scholar
• Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry 2003;160:1286–90
   Google Scholar
• Tohen M, Angst J. Epidemiology of bipolar disorder. In: Tsuang M, Tohen M, editors. Psychiatric epidemiology. New York: Wiley Liss; 2002. p. 427–44
   Google Scholar
• Keck PEJ, McElroy SL, Stanton SP, Bennett JA. Pharmacoeconomic aspects of the treatment of bipolar disorder. Psychiatr Ann 1996;26:449–53
   Google Scholar
• Eastham JH, Jeste DV Young RC. Assessment and treatment of bipolar disorder in the elderly. Drugs Aging 1998;12:205–24
   PubMed Web of Science ®Google Scholar
• Tohen M, Hennen J, Zarate C, Baldessarini R, Strakowski S. Two-year syndromal and functional recovery in 219 cases of firstepisode major affective disorder with psychotic features. Am J Psychiatry 2000;157: 220–8
   Google Scholar
• Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002;24:1668–76
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;141:1–36
   Google Scholar
• Anon. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry 2002;159:1–39
   Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. J Am Med Assoc 1994;271:918–24
   PubMed Web of Science ®Google Scholar
• Pope HGJ, McElroy SL, Keck PEJ, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62–8
   PubMed Web of Science ®Google Scholar
• Keck Jr PE, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998;59:74–81
   Google Scholar
• Bowden C, Calabrese J, McElroy S, Gyulai L, Wassef A. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57: 481
   Google Scholar
• Tohen M. The adverse effect profile and safety of divalproex. Rev Contemp Pharmacother 1995;6:587–95
   Google Scholar
• Tohen M. Mania. In: Seder LI, Rothschild AJ, editors. Acute care psychiatry diagnosis & treatment. Baltimore (MD): Willams & Wilkins; 1997
   Google Scholar
• Tohen M, Zhang F, Taylor C, et al. A meta-analytic study of the use of typical antipsychotic agents in bipolar disorders. J Affect Disord 2001;65:85–93
   PubMedGoogle Scholar
• Bhana N, Perry CM. Olanzapine – a review of its use in the treatment of bipolar I disorder [review]. CNS Drugs 2001;15:871–904
   PubMed Web of Science ®Google Scholar
• Tohen M, Anger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702–9
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841–9
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW Altshuler L, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011–7
   PubMed Web of Science ®Google Scholar
• Zajecka J, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148–55
   PubMed Web of Science ®Google Scholar
• Tohen MT, Ketter T, Zarate C, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263–71
   PubMed Web of Science ®Google Scholar
• Revicki D, Paramore L, Sommerville K, et. al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64:288–94
   PubMed Web of Science ®Google Scholar
• Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost- effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999;60:38–45
   Google Scholar
• Del Paggio D, Finley P, Cavano J. Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population. Clin Ther 2002;24(5):1–15
   Google Scholar
• American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. Washington (DC): 1994
   Google Scholar
• Young RC, Biggs JZ, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429–35
   PubMed Web of Science ®Google Scholar
• Edgell ET, Andersen SW Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone - a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567–79
   PubMed Web of Science ®Google Scholar
• Schoenbaum M, Unutzu J, Sherbourne C, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized clinical trial. J Am Med Assoc 2001;286: 1325–30
   PubMed Web of Science ®Google Scholar
• Coley K, Carter C, DaPos S, Mazwell R, Wilson J, Branch R. Effectiveness of anitipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999;60:850–6
   PubMed Web of Science ®Google Scholar
• Medicare Provider Analysis and Review (MEDPAR). http://cms.hhs.gov: Center for Medicare and Medicaid Services (CMS)
   Google Scholar
• Red book pharmacy's fundamental reference. Montville (NJ): Medical Economics Data Production Company; 2000
   Google Scholar
• Rutten-van Molken MPMH, van Doorslaer EK, van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994;3:333–45
   Google Scholar
• Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68–75
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 1999;15:469–80
   Google Scholar
• Good P. Permutation tests: a practical guide to resampling methods of testing hypotheses. New York (NY): Spring-Verlag; 2000
   Google Scholar
• Altman D. Practical statistics for medical research. New York: Chapman & Hall/CRC; 1999. p.126–30
   Google Scholar
• SAS Institute Inc. SAS/STAT user's guide, version 8, vol. 1. Cary (NC): SAS Institute, Inc.; 1999
   Google Scholar
• Obenchain R, Johnstone B. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Inf J 1999;33:191–209
   Web of Science ®Google Scholar
• Tunis SL, Johnstone BM, Kinon BJ, Barber BL, Browne RA. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 2000;3:232–42
   Google Scholar
• Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997;22:256–66
   PubMed Web of Science ®Google Scholar
• Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57:66–76
   PubMed Web of Science ®Google Scholar
• Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984;5:115–28
   PubMedGoogle Scholar
• Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999;50:1303–8
   PubMed Web of Science ®Google Scholar
• Evans C, Crawford B. Data collection methods in prospective economic evaluation: how accurate are the results? Value in Health 2000;3:277–86
   PubMedGoogle Scholar
• Revicki DA, Frank L. Pharmacoeconomics evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423–34
   PubMed Web of Science ®Google Scholar
• Luna B, Feinglos M. Drug-induced hyperglycemia. J Am Med Assoc 2001;286:1945–8
   PubMed Web of Science ®Google Scholar
• Tunis SL, Ascher-Svanum H, Stensland MD, Kinon BJ. Assessing the value of antipsychotics for treatment of schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics 2004;22:1–8
   PubMed Web of Science ®Google Scholar